PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2015 Views
-
Last post by NHE
-
- 0 Replies
- 925 Views
-
Last post by NHE
-
- 0 Replies
- 9512 Views
-
Last post by NHE
-
- 0 Replies
- 1808 Views
-
Last post by Firidion
-
- 1 Replies
- 1296 Views
-
Last post by vesta
-
- 0 Replies
- 1952 Views
-
Last post by frodo
-
- 0 Replies
- 1874 Views
-
Last post by NHE
-
- 0 Replies
- 1423 Views
-
Last post by NHE
-
- 4 Replies
- 2349 Views
-
Last post by JohnC777